Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.

Tsareva EY, Kulakova OG, Boyko AN, Shchur SG, Lvovs D, Favorov AV, Gusev EI, Vandenbroeck K, Favorova OO.

Pharmacogenomics. 2012 Jan;13(1):43-53. doi: 10.2217/pgs.11.136. Epub 2011 Nov 23.

PMID:
22111603
2.

[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].

Tsareva EIu, Kulakova OG, Makarycheva OIu, Boĭko AN, Shchur SG, Lashch NIu, Popova NF, Gusev EI, Bashinskaia VV, L'vov DV, Favorov AV, Ochs MF, Favorova OO.

Mol Biol (Mosk). 2011 Nov-Dec;45(6):963-72. Russian.

PMID:
22295566
3.

Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients.

Kulakova OG, Tsareva EY, Boyko AN, Shchur SG, Gusev EI, Lvovs D, Favorov AV, Vandenbroeck K, Favorova OO.

Pharmacogenomics. 2012 Nov;13(15):1689-700. doi: 10.2217/pgs.12.161.

PMID:
23171334
4.

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

Kulakova OG, Tsareva EY, Lvovs D, Favorov AV, Boyko AN, Favorova OO.

Pharmacogenomics. 2014 Apr;15(5):679-85. doi: 10.2217/pgs.14.26.

PMID:
24798724
5.

Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.

Sellebjerg F, Hesse D, Limborg S, Lund H, Søndergaard HB, Krakauer M, Sørensen PS.

Mult Scler. 2013 Feb;19(2):179-87. doi: 10.1177/1352458512450353. Epub 2012 May 31.

PMID:
22653658
6.

Vitamin D receptor (VDR) gene SNPs influence VDR expression and modulate protection from multiple sclerosis in HLA-DRB1*15-positive individuals.

Agliardi C, Guerini FR, Saresella M, Caputo D, Leone MA, Zanzottera M, Bolognesi E, Marventano I, Barizzone N, Fasano ME, Al-Daghri N, Clerici M.

Brain Behav Immun. 2011 Oct;25(7):1460-7. doi: 10.1016/j.bbi.2011.05.015. Epub 2011 Jun 12.

PMID:
21664963
8.

Three allele combinations associated with multiple sclerosis.

Favorova OO, Favorov AV, Boiko AN, Andreewski TV, Sudomoina MA, Alekseenkov AD, Kulakova OG, Gusev EI, Parmigiani G, Ochs MF.

BMC Med Genet. 2006 Jul 26;7:63.

9.

Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis.

Wiesemann E, Klatt J, Wenzel C, Heidenreich F, Windhagen A.

Clin Exp Immunol. 2003 Sep;133(3):454-60.

10.

[Genetic predisposition to multiple sclerosis as a polygenic autoimmune disease].

Favorova OO, Favorov AV, Boĭko AN, Sudomoina MA, Andreevskiĭ TV, Alekseenkov AD, Kulakova OG, Gusev EI, Parmigiani G, Ochs MF.

Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(7 Suppl 2):16-22. Russian.

PMID:
19894308
11.
12.

HLA associations with multiple sclerosis in Greece.

Kouri I, Papakonstantinou S, Bempes V, Vasiliadis HS, Kyritsis AP, Pelidou SH.

J Neurol Sci. 2011 Sep 15;308(1-2):28-31. doi: 10.1016/j.jns.2011.06.037. Epub 2011 Jul 8.

PMID:
21741664
13.

Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis.

Sellebjerg F, Hedegaard CJ, Krakauer M, Hesse D, Lund H, Nielsen CH, Søndergaard HB, Sørensen PS.

Mult Scler. 2012 Mar;18(3):305-13. doi: 10.1177/1352458511420268. Epub 2011 Oct 21.

PMID:
22020419
14.

Potential association of vitamin D receptor polymorphism Taq1 with multiple sclerosis.

Cox MB, Ban M, Bowden NA, Baker A, Scott RJ, Lechner-Scott J.

Mult Scler. 2012 Jan;18(1):16-22. doi: 10.1177/1352458511415562. Epub 2011 Aug 3.

PMID:
21816760
15.

Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments.

Gross R, Healy BC, Cepok S, Chitnis T, Khoury SJ, Hemmer B, Weiner HL, Hafler DA, De Jager PL.

J Neuroimmunol. 2011 Apr;233(1-2):168-74. doi: 10.1016/j.jneuroim.2010.10.038. Epub 2010 Nov 27.

PMID:
21115201
16.

Frequency of HLA-DRB1 gene alleles in patients with multiple sclerosis in a Lithuanian population.

Balnytė R, Rastenytė D, Mickevičienė D, Vaitkus A, Skrodenienė E, Vitkauskienė A.

Medicina (Kaunas). 2012;48(1):9-14. Epub 2012 Feb 22.

17.

HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews.

Kwon OJ, Karni A, Israel S, Brautbar C, Amar A, Meiner Z, Abramsky O, Karussis D.

Arch Neurol. 1999 May;56(5):555-60.

PMID:
10328250
18.

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Ambrozak DR, Lovett-Racke AE, Frohman EM, Stastny P, Douek DC, Koup RA, Racke MK.

J Clin Invest. 2002 Mar;109(5):641-9.

19.

No evidence of IL21 association with multiple sclerosis in a Swedish population.

Lindén M, Nohra R, Sundqvist E, Khademi M, Hillert J, Alfredsson L, Olsson T, Kockum I.

Tissue Antigens. 2011 Oct;78(4):271-4. doi: 10.1111/j.1399-0039.2011.01734.x. Epub 2011 Jul 8.

PMID:
21736561
20.

Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis.

Putheti P, Soderstrom M, Link H, Huang YM.

J Neuroimmunol. 2003 Nov;144(1-2):125-31.

PMID:
14597106
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk